Pathological Risk Stratification of Non-Muscle-Invasive and Muscle-Invasive Urothelial Carcinoma for Optimal Therapeutic Decision-Making Pathologische Risikostratifizierung des nicht muskelinvasiven und muskelinvasiven Urothelkarzinoms zur optimalen Therapieentscheidung

Lange F, Gaisa NT, Bolenz C, Klümper N, Roghmann F, Eckstein M (2025)

Publication Type: Journal article

Publication year: 2025

Journal

Aktuelle Urologie Georg Thieme Verlag

DOI: 10.1055/a-2714-2306

Abstract

The treatment of urothelial carcinoma is undergoing rapid change. For both non-muscle-invasive urothelial carcinoma (NMIBC) and muscle-invasive urothelial carcinoma (MIBC), state-of-the-art substances are being tested in various therapy concepts to reduce the risk of recurrence and progression and to increase bladder preservation rates (particularly in muscle-invasive urothelial carcinoma and BCG-refractory high/very high-risk pT1 carcinoma). Antibody-drug conjugates such as enfortumab vedotin, as well as new immunotherapies, play a key role in this context. However, it remains controversial according to which criteria patients with NMIBC should undergo early cystectomy and patients with MIBC should receive bladder-preserving therapy. This paper attempts to discuss the current treatment standards in this controversial context and to address possible histopathological and molecular stratification tools that could improve or guide this selection in the future.

Authors with CRIS profile

Fabienne Lange Institute of Pathology Markus Eckstein Institute of Pathology

Involved external institutions

Universitätsklinikum Ulm DE Germany (DE) Universitätsklinikum Bonn DE Germany (DE) Ruhr-Universität Bochum (RUB) DE Germany (DE)

How to cite

APA:

Lange, F., Gaisa, N.T., Bolenz, C., Klümper, N., Roghmann, F., & Eckstein, M. (2025). Pathological Risk Stratification of Non-Muscle-Invasive and Muscle-Invasive Urothelial Carcinoma for Optimal Therapeutic Decision-Making Pathologische Risikostratifizierung des nicht muskelinvasiven und muskelinvasiven Urothelkarzinoms zur optimalen Therapieentscheidung. Aktuelle Urologie. https://doi.org/10.1055/a-2714-2306

MLA:

Lange, Fabienne, et al. "Pathological Risk Stratification of Non-Muscle-Invasive and Muscle-Invasive Urothelial Carcinoma for Optimal Therapeutic Decision-Making Pathologische Risikostratifizierung des nicht muskelinvasiven und muskelinvasiven Urothelkarzinoms zur optimalen Therapieentscheidung." Aktuelle Urologie (2025).

BibTeX: Download